文献速递中医内科中药与中成药合理使用

基于代谢组学的中西医结合疗效评价:以脾虚型非酒精性脂肪性肝病为例

Appraisal of treatment outcomes in integrative medicine using metabonomics: Taking non-alcoholic fatty liver disease with spleen deficiency syndrome as an example.
PubMed 文献 · J Integr Med · 2022-08-13

针对中西医结合疗效评价中西医疾病概念与中医证候概念之间的鸿沟,本研究以脾虚型非酒精性脂肪性肝病为例,提出基于靶向代谢组学的评价方法。通过研制脾虚证患者报告结局量表、开展纵向干预试验和靶向代谢组学检测,建立整合评价模型。最终模型包含9种核心代谢物,预测概率为83.3%。

要点

  • 整合评价模型含9种核心代谢物,预测概率83.3%。

核心结论

  • 本研究为西医疾病与中医证候的整合疗效评价提供了一条新的综合研究路线。

研究设计与样本

  • 基于文献综述、德尔菲共识调查和信效度检验研制脾虚证患者报告结局量表。
  • 通过纵向干预试验和靶向代谢组学识别脾虚型非酒精性脂肪性肝病治疗的代谢组学基础。
  • 基于先前随机对照试验的治疗反应建立两个各含30名参与者的队列进行靶向代谢组学检测。

主要发现

  • 采用二元逻辑回归初步建立整合评价系统模型,包含9种核心代谢物,预测概率为83.3%。

关键数值与推荐

  • 两个队列各含30名参与者。
  • 整合评价模型包含9种核心代谢物,预测概率83.3%。

临床怎么用

  • 可借鉴本研究的路线,开发中医证候评估工具并结合靶向代谢组学进行中西医结合疗效评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Appraisal of treatment outcomes in integrative medicine is a challenge due to a gap between the concepts of Western medicine (WM) disease and traditional Chinese medicine (TCM) syndrome. This study presents an approach for the appraisal of integrative medicine that is based on targeted metabolomics. We use non-alcoholic fatty liver disease with spleen deficiency syndrome as a test case. METHODS: A patient-reported outcome (PRO) scale was developed based on literature review, Delphi consensus survey, and reliability and validity test, to quantitatively evaluate spleen deficiency syndrome. Then, a metabonomic foundation for the treatment of non-alcoholic fatty liver disease with spleen deficiency syndrome was identified via a longitudinal interventional trial and targeted metabolomics. Finally, an integrated appraisal model was established by identifying metabolites that responded in the treatment of WM disease and TCM syndrome as positive outcomes and using other aspects of the metabonomic foundation as independent variables. RESULTS: Ten symptoms and signs were included in the spleen deficiency PRO scale. The internal reliability, content validity, discriminative validity and structural validity of the scale were all qualified. Based on treatment responses to treatments for WM disease (homeostasis model assessment of insulin resistance) or TCM syndrome (spleen deficiency PRO scale score) from a previous randomized controlled trial, two cohorts comprised of 30 participants each were established for targeted metabolomics detection. Twenty-five metabolites were found to be involved in successful treatment outcomes to both WM and TCM, following quantitative comparison and multivariate analysis. Finally, the model of the integrated appraisal system was exploratively established using binary logistic regression; it included 9 core metabolites and had the prediction probability of 83.3%. CONCLUSION: This study presented a new and comprehensive research route for integrative appraisal of treatment outcomes for WM disease and TCM syndrome. Critical research techniques used in this research included the development of a TCM syndrome assessment tool, a longitudinal interventional trial with verified TCM treatment, identification of homogeneous metabolites, and statistical modeling.

来源:J Integr Med,查看原文。版权归原作者所有。

引用

  1. Dai L, Xu JJ, Zhou WJ, et al. Appraisal of treatment outcomes in integrative medicine using metabonomics: Taking non-alcoholic fatty liver disease with spleen deficiency syndrome as an example. J Integr Med. 2022. PMID: 36031542. doi:10.1016/j.joim.2022.08.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。